share_log

HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $4

HC Wainwright & Co.維持對Medicenna Therapeutics的買入,將目標股價下調至4美元
Benzinga Real-time News ·  2022/08/16 18:28

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Medicenna Therapeutics (NASDAQ:MDNA) with a Buy and lowers the price target from $5 to $4.

HC Wainwright & Co. 分析師Swayampakula Ramakanth維持Medicenna Therapeutics(納斯達克股票代碼:MDNA)的買入並將目標股價從5美元下調至4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論